Last day of #ERS2020 and we are proud to introduce you to the third and last e-Poster about Simeox of the ERS 2020 virtual edition – which title is “Feasibility and benefits of an innovative airway clearance device in COPD patients hospitalized for acute exacerbation”. In this poster, data show that in comparison to standard care, Simeox may improve lung function and quality of life in severe acute exacerbation of COPD
Summary: Airway clearance devices may improve symptoms and lung function in Chronic Obstructive Pulmonary Disease (COPD) with airway mucus hypersecretion. A prospective comparative study aimed to assess the benefits of Simeox technology versus standard care in 32 hospitalized severe COPD patients suffering from chest congestion. Improvement of CAT score was higher in Simeox group ( -34±9% vs control: -24±4%; p<0.001). In very severe COPD (GOLD 4D subgroup), improvement of FEV1 ( +24±10% vs control: +15±5%, p<0.05) and CAT Score ( -33±9% vs control: -24±4%; p<0.05) was higher with Simeox therapy. COPD patients with bronchiectasis seemed to benefit the most from Simeox therapy (FEV1: +28±6%, CAT -38+9%). These results suggested that Simeox may contribute to improving lung function and quality of life in the most severe COPD patients.